#USA #Trailhead Biosystems #Beachwood #iPSC #TrailBio

Trailhead Biosystems Expands Its Cell Lineup with TrailBio® Hematopoietic Progenitor Cells

Trailhead Biosystems, Inc. has made significant strides in biotechnology with their latest launch of TrailBio® hematopoietic progenitor cells. This innovative development marks an important addition to their portfolio of scalable human cell models derived from induced pluripotent stem cells (iPSCs). Developed using a proprietary platform called High-Dimensional Design-of-Experiments (HD-DoE®), these hematopoietic progenitor cells are vital for researchers conducting hematological investigations.

These TrailBio® cells are noteworthy for their expression of key hematopoietic markers, including CD34, CD43, and CD90, which are crucial for the identification and functionality of blood stem cells. Functional characterization studies have validated their ability to form myeloid and erythroid colonies in colony-forming unit assays, as well as their potential to differentiate into various hematopoietic lineages. Additionally, thorough transcriptomic profiling has confirmed their commitment and relevance for hematopoietic studies.

Versatile Research Applications

Designed specifically for varied applications such as disease modeling, drug screening, and hematotoxicity assessments, these hematopoietic progenitor cells offer researchers a reliable human model system. The key advantage lies in their ability to minimize donor variability and enhance result reproducibility, making them an attractive choice for labs tackling blood-related diseases.

David Llewellyn, CEO of Trailhead Biosystems, remarked, "The launch of TrailBio® hematopoietic progenitor cells significantly strengthens our product offering by providing high-quality, human-relevant cell models for researchers. Their consistency and multipotency empower scientists to advance hematopoietic biology investigations and therapeutic innovations."

The scientific community is equally convinced about the benefits of these progenitor cells. Angelica Gomes Ueltschy, Chief Scientific Officer at Trailhead Biosystems, added, "These hematopoietic progenitor cells provide a dependable blend of purity, potency, and versatility. Their high expression of key markers and multi-lineage differentiation capacity makes them exceptionally suited for modeling blood disorders and evaluating therapeutic candidates."

In-depth characterization data and additional information can be accessed on Trailhead's official website, TrailBio.com. This reflects the company's commitment to transparency and accessibility in scientific research.

About Trailhead Biosystems

Founded in 2015 as a spin-off from the Cleveland Clinic and Case Western Reserve University, Trailhead Biosystems, Inc. has solidified its presence as a pioneer in computational approaches to regenerative medicine and drug discovery. With ongoing research initiated by Dr. Jan Jensen, the company utilizes an advanced mathematical modeling and high-throughput robotic manufacturing process through its HD-DoE® platform to develop specialized, high-quality human iPSC-derived cells for drug discovery and cellular therapies. The launch of TrailBio® hematopoietic progenitor cells marks a significant step in bridging the gap between discovery and clinical translation.

For further details about Trailhead Biosystems' innovative products, including the TrailBio® hematopoietic progenitor cells and the HD-DoE® platform, please visit www.TrailBio.com. Research information and inquiries can be directed to Tim Mauk, Corporate Communications at Trailhead Biosystems, via email at [email protected].